Get started
Avenue Therapeutics, Inc.Avenue Therapeutics, Inc.Avenue Therapeutics, Inc.

Avenue Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ATXI chart


Full chart

ATXI upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.53 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−14.20 USD
Net income (FY)
‪−10.38 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪1.84 M‬
Beta (1Y)
−0.86

Employees


Employees (FY)
3
Change (1Y)
+1 +50.00%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−3.46 M‬ USD

About Avenue Therapeutics, Inc.


Sector
Health Technology
CEO
Alexandra MacLean
Headquarters
Bay Harbor Islands
Website
avenuetx.com
Founded
2015
FIGI
BBG00GLTS4V4
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ATXI news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ATXI is 1.86 USD — it has decreased by −4.44% in the past 24 hours. Watch Avenue Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Avenue Therapeutics, Inc. stocks are traded under the ticker ATXI.
ATXI stock has risen by 5.52% compared to the previous week, the month change is a −17.51% fall, over the last year Avenue Therapeutics, Inc. has showed a −84.16% decrease.
We've gathered analysts' opinions on Avenue Therapeutics, Inc. future price: according to them, ATXI price has a max estimate of 8.00 USD and a min estimate of 8.00 USD. Watch ATXI chart and read a more detailed Avenue Therapeutics, Inc. stock forecast: see what analysts think of Avenue Therapeutics, Inc. and suggest that you do with its stocks.
ATXI reached its all-time high on Sep 14, 2020 with the price of 13,882.31 USD, and its all-time low was 1.60 USD and was reached on Nov 15, 2024. View more price dynamics on ATXI chart.
See other stocks reaching their highest and lowest prices.
ATXI stock is 9.88% volatile and has beta coefficient of −0.86. Track Avenue Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Avenue Therapeutics, Inc. there?
Today Avenue Therapeutics, Inc. has the market capitalization of ‪3.53 M‬, it has decreased by −6.52% over the last week.
Yes, you can track Avenue Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Avenue Therapeutics, Inc. is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
ATXI earnings for the last quarter are −1.92 USD per share, whereas the estimation was −0.94 USD resulting in a −104.26% surprise. The estimated earnings for the next quarter are −0.57 USD per share. See more details about Avenue Therapeutics, Inc. earnings.
ATXI net income for the last quarter is ‪−3.08 M‬ USD, while the quarter before that showed ‪−7.19 M‬ USD of net income which accounts for 57.19% change. Track more Avenue Therapeutics, Inc. financial stats to get the full picture.
No, ATXI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 27, 2024, the company has 3.00 employees. See our rating of the largest employees — is Avenue Therapeutics, Inc. on this list?
Like other stocks, ATXI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Avenue Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Avenue Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Avenue Therapeutics, Inc. stock shows the sell signal. See more of Avenue Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.